# US 10,500,220 B2 · Topical compositions > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,500,220 B2 - Document ID: US10500220B2 - Status: Granted - Kind: B2 - Application number: 16/209,542 - Filed: 2018-12-04 - Published: 2019-06-13 - Granted: 2019-12-10 - Earliest claimed: 2011-07-05 - Assignees: Novan, Inc. - Applicants: Novan, Inc. - Inventors: Ryan Doxey; Nathan Stasko - Web page: https://patentgrep.com/patent/US10500220B2 ## CPC - A61K 31/695: Silicon compounds - A61K 8/34: Alcohols - A61K 8/345: {containing more than one hydroxy group} - A61K 8/368: with carboxyl groups directly bound to carbon atoms of aromatic rings - A61K 8/40: containing nitrogen (quinones containing nitrogen A61K8/355) - A61K 8/585: {Organosilicon compounds} - A61K 8/731: {Cellulose; Quaternized cellulose derivatives} - A61K 8/891: saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers - A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids - A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) - A61K 47/38: Cellulose; Derivatives thereof - A61P 17/00: Drugs for dermatological disorders - A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like - A61P 17/10: Anti-acne agents - A61Q 19/00: Preparations for care of the skin - A61K 9/143: {with inorganic compounds} - A61K 2800/22: Gas releasing - A61K 2800/31: Anhydrous - A61K 2800/56: Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms - A61K 2800/592: Mixtures of compounds complementing their respective functions - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS ## Abstract Provided herein are anhydrous compositions that include at least one viscosity increasing agent, at least one organic solvent and at least one humectant. Such compositions may also include at least one active pharmaceutical ingredient (API) and/or at least one water repellant. Related compositions, methods and kits are also provided. ## Claims ### Claim 1 A method of decreasing abnormal keratinization, reducing microbial colonization, reducing inflammation and/or decreasing sebum production in a subject in need thereof, the method comprising applying an anhydrous composition to the skin of a subject to treat the dermatological condition, wherein the anhydrous composition consists essentially of: hydroxypropyl cellulose at a concentration in a range of 0.5% to about 2% by weight of the anhydrous composition, ethanol or isopropyl alcohol at a concentration in a range of 45% to 90% by weight of the anhydrous composition, hexylene glycol at a concentration of about 10% by weight of the anhydrous composition, cyclomethicone at a concentration of about 2.5% by weight of the anhydrous composition, and a nitric oxide (NO)-releasing compound at a concentration in a range of 0.01% to 40% by weight of the anhydrous composition, wherein the method decreases abnormal keratinization, microbial colonization, inflammation, and/or sebum production in the skin of the subject. ### Claim 2 (depends on 1) The method of claim 1, wherein the subject has acne and the method comprises treating the acne. ### Claim 3 (depends on 1) The method of claim 1, wherein the anhydrous composition comprises ethanol. ### Claim 4 (depends on 1) The method of claim 1, wherein the anhydrous composition comprises isopropyl alcohol. ### Claim 5 (depends on 1) The method of claim 1, wherein the NO-releasing compound is present in the anhydrous composition at a concentration in a range of 0.01% to 30% by weight of the anhydrous composition. ### Claim 6 (depends on 1) The method of claim 1, wherein the NO-releasing compound is present in the anhydrous composition at a concentration in a range of 0.01% to 2% by weight of the anhydrous composition. ### Claim 7 (depends on 1) The method of claim 1, wherein the hydroxypropyl cellulose is present in the anhydrous composition at a concentration in a range of 0.5% to about 1% by weight of the anhydrous composition. ### Claim 8 (depends on 1) The method of claim 1, wherein the hydroxypropyl cellulose is present in the anhydrous composition at a concentration of about 1% by weight of the anhydrous composition. ### Claim 9 (depends on 1) The method of claim 1, wherein the NO-releasing compound is present in the anhydrous composition at a concentration of about 1% by weight of the anhydrous composition. ### Claim 10 (depends on 1) The method of claim 1, wherein the NO-releasing compound is present in the anhydrous composition at a concentration of about 2% by weight of the anhydrous composition. ### Claim 11 (depends on 1) The method of claim 1, wherein the NO-releasing compound is present in the anhydrous composition at a concentration of about 4% by weight of the anhydrous composition. ### Claim 12 (depends on 1) The method of claim 1, wherein the NO-releasing compound is present in the anhydrous composition at a concentration of about 8% by weight of the anhydrous composition. ### Claim 13 (depends on 1) The method of claim 1, wherein the NO-releasing compound is present in the anhydrous composition at a concentration of about 12% by weight of the anhydrous composition. ### Claim 14 (depends on 1) The method of claim 1, wherein the NO-releasing compound is present in the anhydrous composition at a concentration of about 16% by weight of the anhydrous composition. ### Claim 15 (depends on 1) The method of claim 1, wherein the NO-releasing compound is present in the anhydrous composition at a concentration of about 20% by weight of the anhydrous composition. ### Claim 16 (depends on 1) The method of claim 1, wherein the NO-releasing compound is present in the anhydrous composition at a concentration of about 24% by weight of the anhydrous composition. ### Claim 17 (depends on 1) The method of claim 1, wherein the NO-releasing compound is present in the anhydrous composition at a concentration of about 30% by weight of the anhydrous composition. ### Claim 18 (depends on 1) The method of claim 1, wherein the NO-releasing compound is present in the anhydrous composition at a concentration of about 32% by weight of the anhydrous composition. ### Claim 19 (depends on 1) The method of claim 1, wherein the NO-releasing compound comprises diazeniumdiolated co-condensed silica particles. ### Claim 20 (depends on 1) The method of claim 1, wherein the method decreases abnormal keratinization in the skin of the subject. ### Claim 21 (depends on 1) The method of claim 1, wherein the method decreases microbial colonization in the skin of the subject. ### Claim 22 (depends on 1) The method of claim 1, wherein the method decreases inflammation in the skin of the subject. ### Claim 23 (depends on 1) The method of claim 1, wherein the method decreases sebum production in the skin of the subject. ### Claim 24 A method of treating a dermatological condition, the method comprising applying an anhydrous composition to the skin of a subject to treat the dermatological condition, wherein the anhydrous composition consists essentially of: hydroxypropyl cellulose at a concentration in a range of 0.5% to about 2% by weight of the anhydrous composition, ethanol or isopropyl alcohol at a concentration in a range of 45% to 90% by weight of the anhydrous composition, hexylene glycol at a concentration of about 10% by weight of the anhydrous composition, cyclomethicone at a concentration of about 2.5% by weight of the anhydrous composition, and a nitric oxide (NO)-releasing compound at a concentration in a range of 0.01% to 40% by weight of the anhydrous composition, wherein the dermatological condition comprises acne, a scar, a wound, and/or a biofilm. ### Claim 25 (depends on 24) The method of claim 24, wherein the dermatological condition comprises acne. ### Claim 26 (depends on 24) The method of claim 24, wherein the dermatological condition comprises a scar. ### Claim 27 (depends on 24) The method of claim 24, wherein the dermatological condition comprises a wound. ### Claim 28 (depends on 24) The method of claim 24, wherein the dermatological condition comprises a biofilm.